🇺🇸▼
For a long time, the likelihood of surviving pancreatic cancer has been extremely low. For patients who were diagnosed with metastatic pancreatic cancer between 2015 and 2021, about 97% died within five years of their diagnosis. This statistic highlights the urgent need for better treatments for a disease that has historically been difficult to defeat.
Pancreatic cancer is so deadly in part because there are no effective screening tests. It rarely causes noticeable symptoms in its earliest stages. By the time a patient experiences signs, such as jaundice, which is a yellowing of the skin, or abdominal pain, the cancer has often already spread to other organs. Early detection is rare, making treatment much harder and less effective when it finally begins.
As a gastrointestinal oncologist and researcher specializing in early-phase clinical trials, I have seen the critical need for more effective therapies for patients with pancreatic cancer. For decades, successfully targeting the central mechanism that causes the vast majority of pancreatic cancers was considered impossible. Scientists believed that the specific genetic errors driving these tumors could not be stopped with medication. However, that narrative is rapidly changing with a new drug that can shut down the key protein that drives pancreatic cancer. This new treatment has nearly doubled survival rates for patients with advanced stages of the disease.
The standard treatment for advanced pancreatic cancer has historically relied on chemotherapy. These are potent drugs designed to kill rapidly dividing cells. While chemotherapy can slow the progression of the disease, its effectiveness is often limited by the ability of pancreatic cancer cells to develop resistance against these drugs. Cancer cells learn to survive the poison, rendering the treatment ineffective over time.
Pancreatic cancer’s success lies in its genetics. More than 90% of pancreatic tumors are driven by mutations in a gene called KRAS. This gene codes for proteins that function as switches that turn cell growth on and off. In a healthy body, these switches work properly, controlling when cells should grow and when they should stop. When the KRAS gene is mutated, the switch becomes permanently stuck in the “on” position. This error commands cancer cells to multiply endlessly, forming tumors and spreading to other parts of the body.
For decades, scientists considered KRAS to be “undruggable.” The surface of the protein is exceptionally smooth. It lacks the molecular pockets that standard drugs require to bind to and turn the switch off. Imagine trying to pick a lock with a smooth, flat key. The key simply has no place to grip or turn. Without a place to attach, traditional drugs could not stop the KRAS protein from signaling cancer cells to grow.
Because existing drugs have not been able to target this protein, treatment for pancreatic cancer has primarily relied on toxic drugs that act more like blunt instruments than precise tools. Chemotherapy attempts to control the disease through widespread cell destruction. This approach causes significant collateral damage to healthy tissues that divide quickly, such as hair follicles and digestive lining. This leads to severe side effects for patients, including hair loss, nausea, and weakness, while often failing to cure the cancer.
A new drug called daroxonrasib offers a critical advance in treating metastatic pancreatic cancer. It represents a major shift from blunt-force chemotherapy to precise, targeted therapy. Daroxonrasib is taken daily by mouth, making it convenient for patients to manage at home. Instead of binding to KRAS directly, it attaches to a molecule called cyclophilin A in cells. This molecule helps fold proteins into their final 3D structures, which is essential for their function.
The drug works by creating a complex that can bind to the active KRAS protein. This process effectively shuts down KRAS’s ability to signal cancer cells to multiply. By stopping the growth signal, the drug slows or stops the tumor’s expansion. The company developing the drug, Revolution Medicines, presented results on May 31, 2026, from its Phase 3 clinical trial. This large study included 500 patients with metastatic pancreatic cancer who had received prior treatment. The goal was to see if this new drug could improve outcomes for those who had not responded well to previous therapies.
The results were significant. Compared to standard chemotherapy, daroxonrasib nearly doubled overall survival from 6.7 months to 13.2 months after diagnosis. This is a substantial increase in life expectancy for patients with an aggressive and terminal illness. Overall, daroxonrasib reduced the risk of death for metastatic pancreatic cancer patients by 60%. This means that patients taking this new drug were much more likely to live longer than those taking the standard chemotherapy treatment.
The most common side effect is a prominent skin rash, which affected more than 86% of patients in the study. Patients also frequently dealt with stomatitis, which is painful swelling and sores inside the mouth. Other side effects included diarrhea, nausea, and vomiting. These symptoms can be uncomfortable and affect daily life. However, patients taking daroxonrasib were far less likely to stop treatment due to severe side effects compared to chemotherapy. They also reported improved quality of life with reduced pain. The precision of the drug means it spares healthy cells, leading to fewer debilitating side effects.
By successfully targeting the specific genetic mutation that drives the vast majority of pancreatic cancers, researchers have demonstrated that this “undruggable” disease is treatable with targeted therapy. This milestone proves that even the most difficult genetic errors in cancer can be addressed with the right scientific approach. It gives hope to patients and families who have faced limited options in the past.
The immediate next step is regulatory review of the drug’s readiness for the clinic. With data now officially published, Revolution Medicines will use these findings to seek formal approval from the Food and Drug Administration and other global regulatory bodies. These agencies must ensure that the drug is safe and effective before it can be prescribed to the general public. This process involves a thorough examination of the clinical trial data, manufacturing quality, and potential risks.
Because advanced pancreatic cancer is notoriously difficult to treat, breakthrough therapies that demonstrate this kind of significant survival benefit are often granted expedited or priority review. This means the regulatory agencies may speed up their evaluation to get the drug to patients faster. When daroxonrasib becomes available to patients will depend on the review timeline. Should the drug obtain approval, it could be available in clinics within months. This accelerated path acknowledges the critical need for new treatments in this area.
For the broader landscape of drug development, this milestone represents a likely shift in pancreatic cancer treatment. I expect more clinical trials exploring combination therapies. These trials will pair KRAS inhibitors like daroxonrasib with other drugs to prevent tumors from developing resistance to treatment. Cancer cells are adaptable, and they may eventually find a way around a single drug. Combining drugs that attack the cancer from different angles can help overcome this resistance and improve long-term outcomes.
Should daroxonrasib succeed, it could help set the stage for more precise, personalized and effective treatments for pancreatic cancer in the years to come. The success of this drug validates the strategy of targeting specific genetic mutations. It opens the door for similar treatments for other cancers driven by difficult-to-reach proteins. This is not just a victory for one drug, but a new era in oncology where once-incurable diseases become manageable conditions.